HU-345

HU-345 is a synthetic cannabinoid that was discovered in the late 20th century. It is a derivative of HU-210, which is itself a synthetic cannabinoid. HU-345 is known for its potential therapeutic effects, particularly in the treatment of pain and inflammation.

History

HU-345 was first synthesized in the late 20th century by a team of researchers at the Hebrew University of Jerusalem. The team was led by Raphael Mechoulam, a renowned chemist known for his work in the field of cannabinoid research. The compound was developed as part of a series of synthetic cannabinoids, which also includes HU-210 and HU-331.

Chemistry

HU-345 is a synthetic cannabinoid, which means it is a man-made compound that mimics the effects of natural cannabinoids found in the cannabis plant. It is a derivative of HU-210, which is one of the most potent synthetic cannabinoids known. HU-345 is structurally similar to HU-210, but it has a different chemical composition that gives it unique properties.

Pharmacology

The pharmacological effects of HU-345 are not fully understood, but it is known to interact with the cannabinoid receptors in the body. These receptors are part of the endocannabinoid system, which plays a key role in regulating a variety of physiological processes, including pain, mood, appetite, and sleep.

Potential Therapeutic Uses

Research into the potential therapeutic uses of HU-345 is still in its early stages, but preliminary studies suggest that it may have potential in the treatment of pain and inflammation. However, more research is needed to fully understand the therapeutic potential of this compound.

See Also

• Cannabinoid
• Cannabinoid receptor
• Endocannabinoid system
• HU-210
• HU-331
• Raphael Mechoulam

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  HU-345 Structure